RARE – ultragenyx pharmaceutical inc. (US:NASDAQ)
Stock Stats
News
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at JPMorgan Chase & Co. from $105.00 to $102.00. They now have an "overweight" rating on the stock.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $121.00 price target on the stock.
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $109.00 to $121.00. They now have a "buy" rating on the stock.
Form SC 13G/A Ultragenyx Pharmaceutica Filed by: RTW INVESTMENTS, LP
Form 8-K Ultragenyx Pharmaceutica For: Nov 09
Form 10-Q Ultragenyx Pharmaceutica For: Sep 30
Form 8-K Ultragenyx Pharmaceutica For: Nov 05
Form 4 Ultragenyx Pharmaceutica For: Oct 10 Filed by: Horn Howard
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.